Avid Bioservices Inc (CDMO)

[cjgaddy]

Jeffery Kraws, CEO of Crystal Research Associates, is the analyst that Peregrine had prepare the 5-17-10 80-pg “PPHM Executive Info. Report”, and the 16-pg 8-3-10 Update...

The last page of 5-17-10 report ( http://www.crystalra.com/pdf/PPHM_EIO_05-17-2010.pdf ) and the 8-3-10 update ( http://www.crystalra.com/pdf/PPHM_FY2010%20Update_08-03-2010.pdf
) says:
Jeffery J. Kraws [Pharmaceutical Analyst] & Karen B. Goldfarb
[e-mail] http://www.crystalra.com

Mr. Kraws does a large number of media interviews, doing repeated TV interviews with Fox Business, Bloomberg, and CNBC. The Crystal website has 20+ media interview clips of Jeff Kraws doing interviews on business shows:
http://www.crystalra.com/about/media.php (click VIEW-ALL in each category)

For example:
“On Jan. 21, 2010, Jeff Kraws, CEO of Crystal Research Associates, was interviewed by FOX Business Television discussing the current status of the H1N1 pandemic and its effect on several pharmaceutical companies, which have been experienced...”

The $54k Peregrine paid to prepare the report may be worth every penny just for the media exposure he may bring to us in the future, given the right news & circumstances. He clearly knows all about us now and has the channels available to spread the word if and when he chooses.

= = = = = = = = =
Jeffrey J. Kraws (BOD, Adeona Pham.)
45 Years Old
http://people.forbes.com/profile/jeffrey-j-kraws/64007
…Mr. Kraws is CEO & co-founder of Crystal Research Associates. Well known and respected on Wall Street, Mr. Kraws has received some of the most prestigious awards in the industry. Among other awards, he was given a “5-Star Rating” in 2001 by Zacks and was ranked the #1 analyst among all pharmaceutical analysts for stock performance in 2001 by Starmine.com . Prior to founding Crystal Research Associates, Mr. Kraws served as co-president of The Investor Relations Group (IRG), a firm representing primarily under-followed, small-capitalization companies. Previously, Mr. Kraws served as a managing director of healthcare research for Ryan Beck & Co. and as director of research/senior pharmaceutical analyst and managing director at Gruntal & Co. (prior to its merger with Ryan Beck & Company). Mr. Kraws served as managing director of the healthcare research group and senior pharmaceutical analyst at First Union Securities (formerly EVEREN Securities); as senior U.S. pharmaceutical analyst for the Swedish-Swiss conglomerate Asea Brown Boveri; and as managing director & president of the Brokerage/Investment Banking operation of ABB Aros Securities, Inc. He also served as senior pharmaceutical analyst at Nationsbanc Montgomery Securities, BT Alex Brown & Sons, and Buckingham Research. Mr. Kraws also has industry experience, having been responsible for competitive analysis within the treasury group at Bristol-Myers-Squibb Company. He holds an MBA from Cornell University and a B.S. degree from State University of New York-Buffalo…